Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Asociación para Evitar la Ceguera en México

Status and phase: Withdrawn; Phase 3

Conditions: Multifocal Choroiditis; Serpiginous Choroiditis; Vogt Koyanagi Harada Disease

Treatments: Drug: Bevacizumab; Procedure: Intravitreal Injection of Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00407121

APEC-0025

Details and patient eligibility

About

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Sex: All

Ages: 25 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical Diagnose
• Patient Consent
• Chronic stage of inflammation

Exclusion criteria

• only eye
• age lower than 30 yo.
• Systemic condition

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)